ROCKET PHARMACEUTICALS INC

Insider selling at Rocket Pharma shows steady, tax‑driven RSU sales—no red flag yet, but investors should watch cumulative volume for liquidity clues.

CEO Shah Gaurav’s recent sale of 2,837 Rocket Pharmaceuticals shares is a routine tax‑related move; insiders still hold 28%—showing confidence in the gene‑therapy pipeline and a stable, attractive investment at a low P/E.

COO Stevens James sells 36,658 Rocket Pharma shares for tax, not profit. See how this routine RSU liquidation fits into the company’s insider‑activity pattern and what it means for investors.

Insider buying shows confidence in Rocket Pharmaceuticals as its Danon disease trial gains traction – learn why senior leaders are buying shares and what it means for investors.

Rocket insider sales show routine RSU tax moves, not a bleak outlook. Learn why the stock’s short‑term volatility is likely a liquidity event, not a loss of confidence.

Insider sales at Rocket Pharmaceuticals spike amid a 48% year‑to‑date drop, but the moves mainly cover tax on RSUs—are they a warning or normal liquidity?

Insider sales spike at Rocket Pharmaceuticals as shares rally – insiders selling to take profits, not fear, amid a speculative surge.

Insider selling at Rocket Pharmaceuticals signals caution: CEO and counsel liquidated shares amid a fragile stock, hinting at a possible short‑term correction or strategic pivot.

CEO’s bulk purchase of Rocket Pharma shares signals strong insider confidence amid market volatility, hinting at future upside if clinical milestones materialize.